Noemí Cerulla1,2,3, Àngels Arcusa4, José-Blas Navarro5, Nuria de la Osa3, Maite Garolera2,6, Cristina Enero7, Glòria Chico1,2, Luís Fernández-Morales4,8. 1. a Memory Unit , Consorci Sanitari de Terrassa (CST), Terrassa , Barcelona , Spain. 2. b Brain, Cognition and Behaviour Research Group , Unitat d'Investigació biomèdica UAB-CST (UIB), Terrassa , Barcelona , Spain. 3. c Department of Clinical and Health Psychology , Universitat Autònoma de Barcelona (UAB), Bellaterra , Barcelona , Spain. 4. d Department of Oncology , Consorci Sanitari de Terrassa (CST), Terrassa , Barcelona , Spain. 5. e Department of Psychobiology and Methodology of Health Sciences , Universitat Autònoma de Barcelona (UAB), Bellaterra , Barcelona , Spain. 6. f Neuropsychology Unit , Consorci Sanitari de Terrassa (CST), Terrassa , Barcelona , Spain. 7. g Department of Mental Health , Consorci Sanitari de Terrassa (CST), Terrassa , Barcelona , Spain. 8. h Department of Oncology , Corporació Sanitària Parc Taulí, Sabadell , Barcelona , Spain.
Abstract
Chemotherapy-Related Cognitive Impairment (CRCI) can be an adverse effect in women treated for breast cancer. Some longitudinal studies reported deficits in attention, memory, and executive function following treatment, but other studies did not find cognitive changes. It is known that practice effects (PE) on repeated assessments with cognitive tests contribute to the discrepancies in these results, but its influence on scores has not been systematically explored. The present study examines the impact of PE on retest scores in a group of women with breast cancer treated with chemotherapy and evaluated longitudinally. METHOD: 51 women with breast cancer treated with a combination of 5-fluorouracil, epirubicin, and cyclophosphamide with or without taxanes were assessed after surgery but before chemotherapy (T1), post-chemotherapy (T2), and at one year after T2 (T3). Longitudinal changes on cognitive performance were analyzed twice: when retest scores were not corrected for PE and when correction for PE was applied to T2 and T3 scores. RESULTS: When PE was not corrected, progressive improvement over time in measures of memory and divided attention at T2 and T3 was observed. In contrast, when PE was corrected, worsening was found in measures of memory, fluency, executive function, and attention at T2 and in attention and executive function at T3. Results after correction for PE are in line with previous longitudinal studies that report cognitive impairment after treatment with chemotherapy for breast cancer. CONCLUSION: Accounting for PE is recommended to identify true change on cognition through treatment with chemotherapy for breast cancer.
Chemotherapy-Related Cognitive Impairment (CRCI) can be an adverse effect in women treated for breast cancer. Some longitudinal studies reported deficits in attention, memory, and executive function following treatment, but other studies did not find cognitive changes. It is known that practice effects (PE) on repeated assessments with cognitive tests contribute to the discrepancies in these results, but its influence on scores has not been systematically explored. The present study examines the impact of PE on retest scores in a group of women with breast cancer treated with chemotherapy and evaluated longitudinally. METHOD: 51 women with breast cancer treated with a combination of 5-fluorouracil, epirubicin, and cyclophosphamide with or without taxanes were assessed after surgery but before chemotherapy (T1), post-chemotherapy (T2), and at one year after T2 (T3). Longitudinal changes on cognitive performance were analyzed twice: when retest scores were not corrected for PE and when correction for PE was applied to T2 and T3 scores. RESULTS: When PE was not corrected, progressive improvement over time in measures of memory and divided attention at T2 and T3 was observed. In contrast, when PE was corrected, worsening was found in measures of memory, fluency, executive function, and attention at T2 and in attention and executive function at T3. Results after correction for PE are in line with previous longitudinal studies that report cognitive impairment after treatment with chemotherapy for breast cancer. CONCLUSION: Accounting for PE is recommended to identify true change on cognition through treatment with chemotherapy for breast cancer.
Entities:
Keywords:
Breast cancer; chemotherapy; cognitive impairment; neuropsychological assessment; practice effect
Authors: Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann Journal: Drug Saf Date: 2022-05-23 Impact factor: 5.606
Authors: Ana Dias-Carvalho; Mariana Ferreira; Ana Reis-Mendes; Rita Ferreira; Maria Lourdes Bastos; Eduarda Fernandes; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa Journal: Arch Toxicol Date: 2022-03-19 Impact factor: 6.168
Authors: Bihong T Chen; Taihao Jin; Sunita K Patel; Ningrong Ye; Huiyan Ma; Chi Wah Wong; Russell C Rockne; James C Root; Andrew J Saykin; Tim A Ahles; Andrei I Holodny; Neal Prakash; Joanne Mortimer; James Waisman; Yuan Yuan; Daneng Li; Mina S Sedrak; Jessica Vazquez; Vani Katheria; William Dale Journal: Breast Cancer Res Treat Date: 2019-04-13 Impact factor: 4.872
Authors: Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa Journal: Arch Toxicol Date: 2021-11-02 Impact factor: 5.153
Authors: Hairong He; Jianfen Zhang; Na Zhang; Songming Du; Shufang Liu; Guansheng Ma Journal: Int J Environ Res Public Health Date: 2020-11-27 Impact factor: 3.390
Authors: Rafael de la Hoz-Camacho; Ana Luisa Rivera-Lazarín; Jose Manuel Vázquez-Guillen; Diana Caballero-Hernández; Edgar Mendoza-Gamboa; Ana Carolina Martínez-Torres; Cristina Rodríguez-Padilla Journal: EXCLI J Date: 2022-01-10 Impact factor: 4.068